Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies.

Wu J, Hu L, Chen M, Cao W, Chen H, He T.

Onco Targets Ther. 2016 Jul 14;9:4277-88. doi: 10.2147/OTT.S106508. eCollection 2016.

2.

Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.

Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang XA, Mu J, Hu YP, Jiang L, Dong P, Gong W, Liu Y.

Sci Rep. 2016 Jun 10;6:26351. doi: 10.1038/srep26351.

3.

In Vivo GFP Knockdown by Cationic Nanogel-siRNA Polyplexes.

Shrivats AR, Mishina Y, Averick S, Matyjaszewski K, Hollinger JO.

Bioengineering (Basel). 2015 Sep;2(3):160-175. Epub 2015 Jul 22.

4.

Pyruvate Kinase M2: A Potential Target for Regulating Inflammation.

Alves-Filho JC, Pålsson-McDermott EM.

Front Immunol. 2016 Apr 21;7:145. doi: 10.3389/fimmu.2016.00145. eCollection 2016. Review.

5.

PKM2 and cancer: The function of PKM2 beyond glycolysis.

Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, Jiang F.

Oncol Lett. 2016 Mar;11(3):1980-1986. Epub 2016 Jan 29.

6.
7.

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC.

Cancer Res. 2016 Mar 1;76(5):1284-96. doi: 10.1158/0008-5472.CAN-15-2478. Epub 2016 Jan 12.

PMID:
26759242
8.

PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation.

Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, Simmet T, Seufferlein T.

Mol Cancer. 2016 Jan 6;15:3. doi: 10.1186/s12943-015-0490-2.

9.

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK.

Cell Rep. 2015 Dec 22;13(11):2395-402. doi: 10.1016/j.celrep.2015.11.047. Epub 2015 Dec 10.

10.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

PMID:
26683771
11.

GLUT3 and PKM2 regulate OCT4 expression and support the hypoxic culture of human embryonic stem cells.

Christensen DR, Calder PC, Houghton FD.

Sci Rep. 2015 Dec 7;5:17500. doi: 10.1038/srep17500.

12.

Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions.

Silvestri A, Palumbo F, Rasi I, Posca D, Pavlidou T, Paoluzi S, Castagnoli L, Cesareni G.

PLoS One. 2015 Aug 20;10(8):e0136250. doi: 10.1371/journal.pone.0136250. eCollection 2015.

13.

Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.

Godugu C, Doddapaneni R, Patel AR, Singh R, Mercer R, Singh M.

Pharm Res. 2016 Jan;33(1):137-54. doi: 10.1007/s11095-015-1771-6. Epub 2015 Aug 19.

14.

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.

Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, Fave GD, Sette C.

Oncogene. 2016 Apr 21;35(16):2031-9. doi: 10.1038/onc.2015.270. Epub 2015 Aug 3.

PMID:
26234680
15.

Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.

Goswami MT, Chen G, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S.

Oncotarget. 2015 Sep 15;6(27):23445-61.

16.

Biological Relevance and Therapeutic Potential of the Hypusine Modification System.

Pällmann N, Braig M, Sievert H, Preukschas M, Hermans-Borgmeyer I, Schweizer M, Nagel CH, Neumann M, Wild P, Haralambieva E, Hagel C, Bokemeyer C, Hauber J, Balabanov S.

J Biol Chem. 2015 Jul 24;290(30):18343-60. doi: 10.1074/jbc.M115.664490. Epub 2015 Jun 2.

17.

Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.

Wang Y, Zhang X, Zhang Y, Zhu Y, Yuan C, Qi B, Zhang W, Wang D, Ding X, Wu H, Cheng J.

Cancer Biol Ther. 2015;16(6):839-45. doi: 10.1080/15384047.2015.1030551. Epub 2015 May 13.

18.

Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.

Talekar M, Ouyang Q, Goldberg MS, Amiji MM.

Mol Cancer Ther. 2015 Jul;14(7):1521-31. doi: 10.1158/1535-7163.MCT-15-0100. Epub 2015 May 11.

19.

Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases.

Talekar M, Tran TH, Amiji M.

AAPS J. 2015 Jul;17(4):813-27. doi: 10.1208/s12248-015-9772-2. Epub 2015 Apr 29. Review.

20.

Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.

Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ, Yun JP.

Oncotarget. 2015 Mar 30;6(9):6570-83.

Items per page

Supplemental Content

Write to the Help Desk